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Purpose: Adenoid cystic carcinoma (ACC) is a uncommon salivary malignant tumor. Our aim was to review our
experience with parotid ACC, to identify clinical-pathological parameters predictive for outcome.
Materials andmethods:We retrospectively reviewed 228 patients affected by parotid gland carcinomas surgically
treated at our Institution. Forty-four ACCwere included in this study.Multivariate analysis riskmodelswere built
to predict recurrence free probability (RFP), distant recurrence free probability (DRFP), overall survival (OS) and
disease free survival (DFS).
Results: Twenty-one patients (47.7%) died from ACC and 2.3% for other causes. The 41% presented local-regional
recurrence, with a regional-RFP rate of 93%, and the 34% reported distant metastases (DM). The five and ten-year
OS rates were 74% and 50%, respectively.
Conclusions: Recurrences were mainly influenced by the presence of perineural invasion and nerve paralysis,
whilst female gender and age b 50 were predictors for good prognosis.
© 2017 Elsevier Inc. All rights reserved.
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1. Introduction
Adenoid cystic carcinoma (ACC) is a malignant tumor of the head
and neck district, it represents approximately the 1% of all epithelial sal-
ivary carcinomas and most frequently it involves major and minor sali-
vary glands of the oral cavity [1]. It presents three differentmorphologic
patterns of growth, including tubular, cribriform and solid configura-
tion, but all of them are characterized by a locally aggressive clinical
course, with infrequent regionalmetastases, slowly progressive and rel-
atively indolent distant metastasis onset, with a usually fatal outcome
[2]. The estimated 5-year survival rate is approximately 36%, with a
local recurrence rate that ranges from 16% to 85% in accordancewith lit-
erature [3]. Recurrence is usually a sign of incurability, and unpredict-
able factors such as tumor extension along perineurial sheaths and
distant metastasis appearance, notably to the lungs, together with the
ACC rare incidence, make this tumor treatment challenging for every
physicians.
Surgery remains the mainstay of treatment for this pathology, since
its response to radiotherapy and chemotherapy has always resulted un-
foreseeable. Complete local resection is recommended and ipsilateral
cervical lymph node dissection is warranted in case of suspicious
cervical lumps on clinical examination or in case of advanced local dis-
ease [4].
Recent reports have tried to identify clinical and pathological prog-
nostic factors of these patients, but outcomes have generally consisted
on small single-institution retrospective series or cohort of patients af-
fected by ACC involving different anatomical head and neck sites, with-
out focusing on a single specific region [5–8]. Factors that usually
emerge to influence prognosis of parotid malignancies count clinical
stage, bone involvement and resectionmargins status, but these general
variables need to be replaced bymore accurate and specific characteris-
tics that should help in assessing single patient outcome. For instance,
the American Joint Committee on Cancer (AJCC) TNM staging system
[9], according to the T-status, the N-status, and the M-status, does not
add anything to single cancer patient biology, because it does not en-
close more specific variables such perineurial invasion or histologic
grading, tumor site, and other patients characteristics i.e.: age, gender,
smoking status and/or alcohol consumption, type of surgery performed
with/without adjuvant radiotherapy or chemotherapy, late distant me-
tastasis onset [10,11]. Only onemulti center international study [12] has
recently published the first nomogram analysis with the aim to predict
single ACCpatient prognosis usingdifferent clinical and pathological pa-
rameters never established before.
On the wake of this new enthusiasm, we have retrospectively ana-
lyzed our institutional case series of 44 patients affected by ACC with
themain aim to describe their epidemiological, clinical and pathological
characteristics, and to correlate all of these variables to each patient
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outcome in terms of RFP, DRFP, OS and DFS. Secondly, a comparison be-
tween ACC and other 184 parotid carcinomas not classified as ACC has
been performed to refine and distinguish specific ACC prognostic char-
acteristics among multiple other same-site malignancies.
2. Materials and methods
2.1. Study population
Between January 1980 and December 2005, a total of 228 patients
affected by parotid gland carcinomaswere treated at theOtorhinolaryn-
gology University Clinic of Florence and 44 cases out of them received
the diagnosis of ACC. All the participants signed an informed consent
agreement before undergoing surgery. The indications for treatment in-
cluded the presence of a parotid mass with a pre-operative fine-needle
aspiration cytology (FNAC) report indicative for salivary malignancy.
The study was approved by the local institutional review board (IRB)
committee. All patients were reviewed and retrospectively restaged in
accordancewith the 7th edition of American Joint Committee on Cancer
AJCC [9] and with the WHO classification [2].
Patient, tumor, and treatment characteristics were extracted from
each patient notes. Clinical characteristics included patient gender, age
(divided into three different categories: b50 y, 50–70 y, N70 y), cT and
cN status, clinical stage, the presence or absence of clinical facial nerve
paralysis and skin invasion. Tumor characteristics included the presence
of perineurial invasion (PNI), type of pattern of growth (tubular, cribri-
form, solid) [13], pathological T-status (pT), pathological N-status (pT)
and surgical resection margins status. Clear margins were defined as
tumor-free margins ≥5 mm, and positive margins if ≤1 mm3. All of tis-
sue samples were revised by a single pathologist (AF). Treatment char-
acteristics included type of primary tumor resection (superficial
parotidectomy, total parotidectomy with facial nerve preservation and
radical parotidectomy), neck dissection and use of postoperative radia-
tion and/or chemotherapy.
Local, regional and distant recurrences onset were analyzed over a
10-year follow-up period that was done by frequent protocolled outpa-
tient controls i.e.: every 2–3 months during the first two-year post-
treatment period, every 4 months during the third year of clinical con-
trol and six monthly in the fourth and fifth year after treatment. After
5 years clinical control continued yearly for life. Diagnostic imaging, de-
spite not routinely performed, counted CAT scans of head, neck and
chest.
2.2. Statistical analysis
Categorical variables were calculated in terms of frequencies and
percentages for all of the 228 parotid malignancies. First, an internal
analysis of 44 ACC clinical and treatment parameters was performed.
Standard descriptive statistics were used to summarize data, with re-
spect to demographic and clinical characteristics. Chi-squared test, or
Fisher exact test when appropriate, were used to compare the ACC
groups against the other 184 patients.
Outcomewas analyzed by univariate andmultivariate survival anal-
yses, by using STATAversion 12.1 (StataCorp. 2011. Stata Statistical Soft-
ware: Release 12. College Station, TX: StataCorp. LP). Logistic regression
was used to investigate which factors were associated with each re-
sponse variables. Afterwards, multiple logistic regression analyses
were performed to account for several confounding variables simulta-
neously. Multiple logistic regression included all variables of interest,
taking into account multicollinearity and sample size.
The Kaplan–Meier method was used to estimate overall survival
(OS) defined as the period from date of diagnosis to date of death or
last follow-up visit, with patients censored at their last follow-up visit
by patients groups and the Log-Rank test was used to compare survival
curves. The same procedure was used to analyze disease-free survival
(DFS), distant recurrence-free probability (DRFP), disease-specific
survival (DSS), defined as the period from date of diagnosis to date of
local and regional relapse, distant metastasis onset, and death from dis-
ease, respectively, were similarly censored at the last follow-up visit for
all of the clinical and pathological characteristics collected. Hazard ratios
(HRs) with 95% confidence intervals (CIs) were calculated to analyze
the equality of survivor functions by subgroup for the same variables.
A p value b0.05 was considered statistically significant. A two tailed p-
value b0.05 was considered significant.
3. Results
3.1. Continuous data description
Table 1 summarizes patient and disease characteristics for the ACC
groups (n= 44) and the other histologic types of parotid malignancies
rather than ACC (n= 184).
Mean age in the cohort of ACC patients was 54.18 years ± 17.36 SD
(95%CI 48.90–59.46; range 11–83 years), with a slightly female prepon-
derance (52% females vs. 48% males).
More than 70% of patients presented with an intermediate-ad-
vanced T-stage status (cT2 34% and cT3 39%) and the vast majority of
the 44 ACC was cervical lymph node negative (82%). A final clinical
stage status IV was recorded in the 25% of patients. Clinical characteris-
tics of local tumor aggressiveness were documented in the 25% and 9%
of cases, respectively for facial nerve paralysis and skin tumor invasion.
Most patients received conservative surgical treatment (75%) instead of
radical local tumor resection (25% out of 44) but despite the moderate
presence of microscopic positive resection margins (20%), PNI was doc-
umented in half of the case series (50%). The final pathological report
was almost completely in accordance with the clinical tumor staging,
and the distribution of the three patterns of growth saw the cribriform
as the most frequent one (41%), followed by the tubular (32%) and
solid (27%) patterns. Radiotherapy (59% of cases) with concomitant
chemotherapy (14% of cases) were performed for ACC patients when
advanced tumor stage, with/without pathological neck nodes, or pres-
ence of PNI or positive resection margins were documented.
Local relapse appeared in 16 out of 44 patients (36%), whilst regional
recurrence was less represented (7%); distant metastases occurred
mainly in lungs (30%), and other two cases reported brain and bones re-
currences, respectively, with a global rate of 34% of distant metastases.
ACC in comparison to the other 184 parotid malignancies showed a
higher cT stage (p=0.001) and lower presence of neckmetastases (p=
0.039) at the primary diagnosis, together with a higher rate of PNI (p b
0.001) and positive microscopic resection margins (p = 0.017) at the
final pathologic report. Finally, local recurrence and distant metastasis
disease incidence showed a prevalence in the ACC group (p = 0.017
and p= 0.016, respectively).
3.2. Univariate and survival analyses
Table 2 represents survival outcomes stratified by disease and treat-
ment variables at the univariate analysis for the 44 ACC patients; it
shows that ACC local recurrence is mainly influenced by advanced pri-
mary cT stage (cT3, p=0.050), suspected neckmetastasis at the clinical
stage (cN1, p= 0.041) which did not found any statistical significance
at the pathologic N-status; clinical advanced stage presented a progres-
sive worsening of local-DFS with a p value of 0.007 for TNM IV. And, in-
direct signs of local aggressiveness such facial nerve paralysis (p =
0.007), presence of PNI (p = 0.001), corresponded to a worse
local prognosis and together with indications for adjuvant radiotherapy
(p = 0.004). Concerning pathologic patterns of growth the solid
feature was themost represented among a higher incidence of local re-
lapse (p= 0.005).
By comparing the ACC to the other malignancies in terms of local-
DFS (Fig. 1a), it emerged that for the ACC group local relapse incidence
continued to appear over a longer follow-up time (p=0.1975); whilst,
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ACC regional recurrence was influenced by the pathological N-status,
only (p = 0.032). On the contrary, other type of parotid malignancies
showed a higher incidence of regional-recurrence in comparison to
ACC patients during the clinical follow-up (p = 0.2007) (Fig. 1b),
which was mainly influenced by the presence of neck metastasis at
the final pathological report (p b 0.001), PNI (p= 0.003) and positive
microscopic resection margins (p= 0.005).
Distant metastasis (DM) onset in ACC patients was statistically due
to the presence of a solid pattern of growth (p = 0.044). The other
184 malignancies presented an incidence of DM of 15% (28 out of
184), whose appearance resulted to be linked to an advanced clinical
TNM stage (p= 0.042 for stage IV), facial nerve paralysis (p= 0.017),
PNI (p = 0.003) and adjuvant radiotherapy (p = 0.002). Their
Kaplan-Meyer curves (Fig. 1c) evidenced a higher incidence of DM in
the ACC group (34% vs 15%), with their progressive appearance over
the whole long follow-up period of 120 months (p= 0.1402).
Throughout a median follow-up time of 95 months (mean 92.48 ±
50.89 SD; 95% CI 77.01–107.95; range 7–180 months), the 48% of ACC
patients died for disease and one (2%) for other causes. Again, advanced
clinical stage (p= 0.016), facial nerve paralysis at the primary clinical
exam (p = 0.024), PNI (p = 0.001), solid pattern of growth (p =
0.001) and post-operative radiation treatment (p = 0.004) showed
the most statistically significant correlations with mortality rate. The
other type of malignancies presented a global mortality rate of 38.5%,
where 64 patients died for disease (35%) and 5 for other causes (3%).
The OS curves of both groups are represented in Fig. 1d (p= 0.601).
3.3. Multivariate analysis
Despite the absence of significant p values, among the variables
sorted from the univariate analysis, the PNI conserved the highest OR
(14.1) for incidence of local recurrence and facial nerve paralysis was
associated with a higher mortality rate (OR 5.9) (Table 3). Their graphic
representations are shown in Fig. 2a and b.
On the other hand, regional-recurrence and distant metastases mul-
tivariate analyses were not statistically significant enough to organize
their graphics.
4. Discussion
ACC is an uncommon tumor and concerning anatomical site inci-
dence the parotid reports a value between 6–10% of interest [14]. ACC
has classically been described as having an indolent but persistent and
recurrent growth and, in contrast to other epithelial malignancies
with poor prognosis, ACC has a good 5-year survival rate. ACC is a dis-
ease with long evolution, featuring recurrence, not so much locally as
by remote metastasis. The literature reports 55–90% 5-year and 30–
70% 10-year overall survival [15], and accordingly, our results showed
howoverall survival continues to drop after the 5-year followupperiod,
producing considerably lower 10-year survival rate (Fig. 1d) in accor-
dance with literature results [16,17].
In our single center cohort of studywe retrospectively reviewed sev-
eral clinical-pathological parameters found to affect ACC patients prog-
nosis; in specific, accordingly to literature, the advanced cT and clinical
tumor stage, positive pathological N-stage, the presence of PNI or of a
solid pattern of growth, and a positive microscopic resection margins
status have been considered suggestive for severe outcome. On the
other hand, low malignancies (tubular and cribriform) and tumor-free
surgical margins have been correlated to a better local control rate,
lower incidence of early metastasis and better mortality rate [18–21].
In specific we found that ACC in comparison to the other 184 parotid
malignancies showed a higher cT stage (p=0.001) and lower presence
of neck metastases (p=0.039) at the primary diagnosis, together with
a higher rate of PNI (p b 0.001) and positive microscopic resection mar-
gins (p= 0.017) at the final pathologic report, and these resulted to be
main factors influencing prognosis in terms of local-relapse incidence,
DM appearance and cancer specific mortality.
Local relapse, DM and mortality reported a progressive decrease
over 10 years of clinical follow-up (Fig. 1a, c, d), where the above men-
tioned variables were the main prognostic factors involved except for
Table 1
Clinical characteristics of 44 ACC.
Variables Level ACC
N (%)
Others
N (%)
p-Value
Gender Female 23 (52) 71 (39) 0.098
Male 21 (48) 113 (61)
Age b50 165
(34)
50 (27) 0.416
50–70 22 (50) 89 (48)
N70 7 (16) 45 (25)
cT T1 8 (18) 30 (16) 0.001
T2 15 (34) 79 (43)
T3 17 (39) 26 (14)
T4a 4 (9) 49 (27)
cN N0 36 (82) 151 (82) 0.039
N1 7 (16) 11 (6)
N2a 0 (0) 6 (3)
N2b 0 (0) 14 (7)
N2c 1 (2) 1 (1)
N3 0 (0) 1 (1)
Clinical stage 1 7 (16) 28 (15) 0.325
2 14 (32) 68 (37)
3 12 (27) 29 (16)
4 11 (25) 59 (32)
Facial nerve paralysis No 33 (75) 151 (82) 0.286
Yes 11 (25) 33 (18)
Skin invasion No 40 (91) 179 (97) 0.051
Yes 4 (9) 5 (3)
Type of surgery Radical parotidectomy 11 (25) 60 (32) 0.723
Total parotidectomy +
facial nerve
preservation
32 (73) 118 (64)
Superficial
parotidectomy
1 (2) 6 (3)
Perineurial invasion No 22 (50) 160 (87) b0.001
Yes 22 (50) 24 (13)
Cribriform pattern No 26 (59)
Yes 18 (41)
Tubular pattern No 30 (68)
Yes 14 (32)
Solid pattern No 32 (73)
Yes 12 (27)
pT T1 8 (18) 32 (17) 0.016
T2 16 (36) 73 (40)
T3 14 (32) 25 (14)
T4a 6 (14) 54 (29)
pN N0 36 (82) 136 (84) 0.578
N1 6 (14) 19 (10)
N2a 1 (2) 7 (4)
N2b 1 (2) 18 (10)
N2c 0 (0) 2 (1)
N3 0 (0) 2 (1)
Resection margins
status
No 35 (80) 169 (92) 0.017
Yes 9 (20) 15 (8)
Radiotherapy No 18 (41) 75 (41) 0.986
Yes 26 (59) 109 (59)
Chemotherapy No 38 (86) 172 (93) 0.116
Yes 6 (14) 12 (7)
Local recurrence No 28 (64) 148 (80) 0.017
Yes 16 (36) 36 (20)
Regional recurrence No 41 (93) 162 (88) 0.327
Yes 3 (7) 22 (12)
Distant metastasis No 29 (66) 156 (85) 0.016
Polmone 13 (30) 23 (12)
Ossa 1 (2) 4 (2)
Cerebrale 1 (2) 1 (1)
Death No 22 (50) 113 (61) 0.164
Yes 21 (48) 70 (38)
Yes, other 1 (2) 1 (1)
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theDM incidencewhichwas affectedmainly by solid pathologic pattern
of growth.
By analyzing each single significant factor, perineurial invasion has
already shown its association with a high local failure in head and
neck cancers [22], and the reason lays in the correlated high probability
of residual microscopic disease in adjacent tissues. In contrast with this,
positivemicroscopic resectionmargins status resulted in our case series
to be a strong predictor in all survival analyses for all parotid malignan-
cies rather than the ACC, suggesting a more important prognostic role
acted by other pathologic variables such PNI and solid pattern of
growth. The vast majority (63%) of ACC neoplasm excisions with clear
marginswere early T-stage (cT1 and cT2) tumors, the reaming cases in-
cluded 10 cT3 and 3 cT4; whilst, among positive resection margins (9
out of 44 cases), seven were represented by advanced stage cancers
(78%). These results are in agree with the general concept that wide re-
section of ACC is mandatory. The percentage of positive margins often
does not reflect the wide surgical intent performed by surgeons and
this might find its reason in the intrinsic nature of ACC neoplasms; it
arises from a not capsulated organ such parotid gland, thus its infiltra-
tive growth is not hindered letting ACC invades adjacent tissue without
well-defined borders and it impactsmainly on local control rate [23,24].
Despite the relatively indolent progress of ACC in about the 50% of
patients, once themetastatic disease is present, it has been documented
that survival rate is about 3 years where most patients die from recur-
rence disease [25]. In literature, the incidence of distantmetastasis is es-
timated to be around 25–55% and usually only 20% of patients with
distant metastasis survive 5-years [19,21]. Here, DM presented a per-
centage of incidence of 34, and the 40% of patients was dead within
the first 60 months of follow-up and it seemed to be mainly influenced
by the solid pattern.
Adjuvant radiotherapy resulted to negatively affect prognosis of ACC
in terms of local relapse incidence, DM appearance and cancer specific
mortality. Its role has been debated, so far [26–28]; in our study, pa-
tientswho received it accordingly to standard treatment concept of rad-
ical resection followed by high radiotherapy dose [29], showed a worse
prognosis, in contrast with other reports where different radiotherapy
protocols showed a significant improvement in local control rate, pro-
gression-free disease survival and over-all survival [30]. These contro-
versies might find a reason in the need to find a balance between
aggressive surgical procedures to obtain clear margins and the intent
to not make post-operative morbidity rate higher than necessary, such
as performing facial nerve sacrifice even when there is no macroscopic
Table 2
Univariate analysis of 44 ACC for local and regional recurrence, distant metastasis onset and mortality rate.
Variables Level Local relapse.
OR (CI) p
Regional relapse
OR (CI) p
DM
OR (CI) p
Mortality
OR (CI) p
Gender Female Ref. Ref. Ref. Ref.
Male 0.52 (0.15, 1.82) 0.307 2.32 (0.19, 27.6) 0.507 0.94 (0.27, 3.27) 0.919 0.99 (0.30, 3.24) 0.989
Age b50 Ref. Ref. Ref. Ref.
50–70 0.65 (0.17, 2.48) 0.532 0.67 (0.04, 11.6) 0.781 1.14 (0.29, 4.55) 0.850 1.37 (0.37, 5.12) 0.638
N70 0.19 (0.02, 1.99) 0.166 2.33 (0.12, 43.8) 0.571 0.8 (0.11, 5.68) 0.823 0.86 (0.14, 5.23) 0.867
cT T1 Ref. Ref. Ref. Ref.
T2 1.1 (0.08, 14.1) 0.955 n.c. 4.7 (0.45, 48.3) 0.196 1.5 (0.22, 10.3) 0.680
T3 10 (0.99, 100) 0.050 n.c. 4.9 (0.49, 49.2) 0.177 5.5 (0.84, 36.2) 0.076
T4a 21 (0.96, 459) 0.053 n.c. 2.3 (0.11, 51.0) 0.590 n.c.
cN N0 Ref. Ref. Ref. Ref.
N1 6.5 (1.08, 39) 0.041 2.8 (0.22, 36) 0.424 1.5 (0.29, 7.81) 0.630 3.1 (0.53, 18.3) 0.206
N2c n.c. n.c. n.c. n.c.
Clinical stage 1 Ref. Ref. Ref. Ref.
2 0.46 (0.02, 8.7) 0.606 n.c. 3.3 (0.31, 36.1) 0.322 0.7 (0.09, 5.4) 0.718
3 3.0 (0.26, 34.2) 0.376 n.c. 4.3 (0.39, 47.6) 0.236 3.5 (0.47, 25.9) 0.220
4 60 (3.1, 1147) 0.007 n.c. 3.4 (0.30, 39.6) 0.324 25 (1.8, 347) 0.016
Facial nerve paralysis No Ref. Ref. Ref. Ref.
Yes 8.3 (1.77, 39.1) 0.007 7.1 (0.58, 87) 0.126 1.14 (0.27, 4.8) 0.854 6.9 (1.28, 37.3) 0.024
Skin invasion No Ref. Ref. Ref. Ref.
Yes 6.23 (0.59, 65.9) 0.128 n.c. 0.62 (0.06, 6.5) 0.690 3.3 (0.32, 34.7) 0.317
Type of surgery Radical parotidectomy Ref. Ref. Ref. Ref.
Total parotidectomy + facial
nerve preservation
0.33 (0.08, 1.4) 0.136 n.c. 0.67 (0.16, 2.7) 0.575 0.50 (0.12, 2.1) 0.337
Superficial parotidectomy 0.28 (0.02, 3.6) 0.326 n.c. n.c. 0.19 (0.01, 2.5) 0.207
Perineurial invasion No Ref. Ref. Ref. Ref.
Yes 17.5 (3.2, 95) 0.001 n.c. 2.8 (0.77, 10.4) 0.117 11.6 (2.8, 47.3) 0.001
Cribriform pattern No Ref. Ref. Ref. Ref.
Yes 0.52 (0.14, 1.91) 0.328 n.c. 0.62 (0.17, 2.26) 0.464 0.47 (0.14, 1.59) 0.223
Tubular pattern No Ref. Ref. Ref. Ref.
Yes 0.19 (0.04, 1.00) 0.050 1.07 (0.09, 13) 0.953 0.41 (0.09, 1.8) 0.234 0.27 (0.07, 1.05) 0.059
Solid pattern No Ref. Ref. Ref. Ref.
Yes 10.7 (2.27, 50.6) 0.003 6.2 (0.51, 75.8) 0.153 4.2 (1.04, 17) 0.044 21 (2.4, 184) 0.006
pT T1 Ref. Ref. Ref. Ref.
T2 1.6 (0.14, 18.6) 0.700 n.c. 4.2 (0.41, 43) 0.227 1.8 (0.27, 12.0) 0.543
T3 9.3 (0.89, 97.7) 0.062 n.c. 3.9 (0.37, 41) 0.260 4.0 (0.59, 27.2) 0.157
T4a 14 (0.94, 207) 0.055 n.c. 7 (0.50, 98) 0.148 n.c.
pN N0 Ref. Ref. Ref. Ref.
N1 2.3 (0.4, 13.1) 0.358 17.5 (1.28, 238) 0.032 2.27 (0.39, 13.1) 0.358 7 (0.74, 66) 0.090
N2a n.c. n.c. n.c. n.c.
N2b n.c. n.c. n.c. n.c.
Resection margin status Negative Ref. Ref. Ref. Ref.
Positive n.c. 2.1 (0.17, 25.7) 0.574 0.96 (0.1, 4.5) 0.957 n.c.
Radiotherapy No Ref. Ref. Ref. Ref.
Yes 23.2 (2.67, 201) 0.004 n.c. 1.63 (0.44, 6.0) 0.464 7.9 (1.9, 31.6) 0.004
Chemotherapy No Ref. Ref. Ref. Ref.
Yes n.c. 3.6 (0.27, 47.3) 0.330 0.96 (0.16, 6.0) 0.966 n.c.
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evidence of disease. The counterpart of a less aggressive surgical tumor
resection, is applying radiotherapy on microscopic close or positive
margins without gaining any additional chances to prevent relapses.
Unfortunately, classical chemotherapies have not proved effective in
ACC so far; and since chemotherapy appears to be ineffective against
most salivary gland ACCs, testing a patient's tumor for sensitivity to a
chemotherapy agent before giving it is recommended thus there are
no convincing data supporting its routine use, except for metastatic dis-
ease [31,32].
Although the indolent course of ACC correlates with relatively ac-
ceptable survival rates, this is a small number of patients, with poor sur-
vival rates and uncontrollable disease progress for which improved and
more effective adjuvant therapymay bewarranted. Our results support
other studies already published in literature [12], based mainly on sin-
gle-Institution case series with different anatomical sites analyzed [5–
8]. Even multi centric studies reporting wider case-series did not focus
on single anatomical site, for instance the REFCOR [4] network provided
a large prospective cohort, considering the rarity of ACC, but follow-up
was insufficient to assess long-term prognostic factors for overall
survival.
Here, we reported an accurate analysis of one single site ACC disease,
the parotid gland, with the highest number of patients so far. Of course,
a number of inherent limitations of the present study need to be ad-
dressed. First, this series was a retrospective study and the patients
were heterogeneous regarding the extent of surgery and radiotherapy.
For the same reason, the correlation between therapy and prognosis
cannot be compared with other reports. At the same time we analyzed
survivals along a long-term follow-up period, even longer than 10 years
in the vast majority of cases. Second, more accurate predictive nomo-
grams should count on larger case series and should study the anatom-
ical site as independent prognostic factor, aswell, in addition to all of the
clinical and pathological characteristics known, to better characterize
the disease and to define optimal treatments.
In summary, despite several limitations, this study comprehensively
analyzed the clinicopathologic features of a large single-Institution and
one-anatomical site case series of ACC to date. In more than half of our
patients, distant metastases was detected later than a 5-year follow-
up period, confirming the delayed appearance reported in the literature.
Development of distant metastasis occurred irrespectively of and de-
spite complete control of the tumor in the primary site. Margin status
(positive versus clear)was significantly associatedwith local recurrence
but not with distant metastasis. No other histological or clinical param-
eter proved to be a reliable prognostic factor for the development of dis-
tant metastases, other than perineural invasion.
Whereas its rarely and the shortage of large case series, some reports
have looked for molecularmarkers to improve prognosis prediction be-
cause of the lack of strong significant correlation between commons
clinical and pathological features with outcomes [13,33]. In this view,
nomograms based on strong prognostic parameters, grounded on
Fig. 1. a) Local DFS curves comparing ACC and other-types groups; b) Regional DFS curves comparing ACC and other-types groups; c) DM DFS curves comparing ACC and other-types
groups; d) OS curves comparing ACC and other-types groups.
Table 3
Multivariate analysis for local-recurrence incidence and mortality rate in ACC patients.
Variables OR 95% CI p-Value
Local-recurrence Radiotherapy 4.7 (0.34, 64.3) 0.247
Solid pattern 1.1 (0.09, 13.8) 0.917
Tubular pattern 0.32 (0.02, 4.6) 0.400
PNI 14.1 (0.90, 220) 0.059
Facial nerve paralysis 3.6 (0.38, 33.2) 0.266
cN positive status 4.9 (0.31, 76.7) 0.259
Mortality rate Solid pattern 4.3 (0.26, 70.6) 0.312
Tubular pattern 0.41 (0.06, 2.6) 0.342
PNI 4.1 (0.65, 25.6) 0.132
Facial nerve paralysis 5.9 (0.81, 43.0) 0.079
pN positive status 4.2 (0.21, 82.9) 0.348
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large case series with a long-time of follow-up up to 20 years since the
primary diagnosis, could help clinicians in identifying high risk patients
who might benefit from a more aggressive combined treatment and
more restricted follow-up.
5. Conclusion
Adenoid cystic carcinoma, even though is a relatively uncommon
neoplasia, proves to be a problematic pathology due tomany controver-
sies existing regarding knowledge about its clinical and biological be-
havior and its treatment's response.
Predictive nomograms, in accordance with Gangly and colleagues
[12], could be useful tolls for patient counseling and treatment decision
making, whichmight guide towardsmore tailored patient care protocol
together with the addition of future possible target therapies.
To reach this purpose further clinical trials are needed.
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